The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
Racial Differences in Diabetic Cardiomyopathy
Batista, J. L., Liu, Y., Butler, J., Prato, S. D., Ezekowitz, J. A., Lam, C. S. P., Marwick, T. H., Rosenstock, J., Tang, W. H. W., Perfetti, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.053 · Cited by 11
Husdal, R., Rosenblad, A., Leksell, J. K., Eliasson, B., Jansson, S. P. O., Jerdén, L., Stålhammar, J., Steen, L., Wallman, T., Svensson, A., et al. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.09.003 · Cited by 11
Self-citationKjær, L. K., Oellgaard, J., Henriksen, T., Gæde, P., Pedersen, O. B., & Poulsen, H. E. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.030 · Cited by 11
Zarrouk, M., Franzén, S., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2019) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2019.01.011 · Cited by 11
Self-citationTancredi, M., Rosengren, A., Svensson, A., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., & Lind, M. (2019) · Open Heart · doi:10.1136/openhrt-2018-000967 · Cited by 11
Self-citationBrüggenwirth, I. M. A., van Reeven, M., Vasiliauskaitė, I., van der Helm, D., van Hoek, B., Schaapherder, A. F., Alwayn, I. P. J., van den Berg, A. P., de Meijer, V. E., Murad, S. D., et al. (2020) · Transplant International · doi:10.1111/tri.13770 · Cited by 11
Kjellberg, J., Tikkanen, C. K., Bagger, M., & Gæde, P. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1837626 · Cited by 11
Nimbekar, T., Jain, A., & Mohanty, P. K. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00359 · Cited by 11
Boswell, L., Serés‐Noriega, T., Mesa, A., Perea, V., Pané, A., Viñals, C., Blanco, J., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01959-z · Cited by 12
Ling, S., Zaccardi, F., Vlacho, B., Li, P., Real, J., Mata‐Cases, M., Franch‐Nadal, J., Kosiborod, M., Gillies, C., Fenici, P., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14856 · Cited by 11
Simmons, D. S., Glenister, K., Magliano, D. J., & Bourke, L. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108492 · Cited by 11
The future of nuclear cardiac imaging: Reflection and a vision
Iskandrian, A. E. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1088-4 · Cited by 11
The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe
Mathieu, C., Söderberg, J. A. E., Prato, S. D., Felton, A.-M., Cos, X., de Beaufort, C. E., Gautier, J., Hauck, B., Forbes, A., Heine, R. J., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05831-1 · Cited by 11
The STC2–PAPP-A–IGFBP4–IGF1 axis and its associations to mortality and CVD in T2D
Gude, M. F., Hjortebjerg, R., Bjerre, M., Charles, M., Witte, D. R., Sandbæk, A., & Frystyk, J. (2023) · Endocrine Connections · doi:10.1530/ec-22-0451 · Cited by 10
Cosson, E., Auzanneau, M., Aguayo, G., Karges, W., Riveline, J., Augstein, P., Sablone, L., Jehle, P. M., Fagherazzi, G., Holl, R. W., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02419-4 · Cited by 10
All-cause mortality and factors associated with it in Finnish patients with type 1 diabetes
Putula, E., Kauppala, T., Vanhamäki, S., Haapakoski, J., Laatikainen, T. K., & Metso, S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108881 · Cited by 12
Shi, C., Zhang, Q., Li, Y., Zhao, J., Wang, C., & Zhang, Y. X. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04427-4 · Cited by 10
Berger, M., Marx, N., & Marx-Schütt, K. (2025) · European Cardiology Review · doi:10.15420/ecr.2024.29 · Cited by 13
Wu, J., Gao, Q., Tian, M., Tan, S., Dong, J., & Wei, H. (2025) · QJM · doi:10.1093/qjmed/hcaf101 · Cited by 10
SNAITH, J. R., Olsen, N., Evans, J., Kowalski, G. M., Bruce, C. R., Samocha‐Bonet, D., Breit, S. N., Holmes-Walker, D. J., & Greenfield, J. R. (2025) · Nature Communications · doi:10.1038/s41467-025-65951-1 · Cited by 10
Analysis of hospitalizations by cardiovascular disease in the population with diabetes in Spain
Zapatero, A., Gómez‐Huelgas, R., Canora, J., Muñoz, J. E., Romero-Sánchez, M., Méndez‐Bailón, M., Marco-Martínez, J., & Barba, R. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.09.006 · Cited by 10
Wube, T. B., Alemayehu, T., & Hirigo, A. T. (2020) · Journal of Diabetes and Endocrinology · doi:10.5897/jde2019.0132 · Cited by 10
Bernfort, L., Husberg, M., Wiréhn, A.-B., Rosenqvist, U., Gustavsson, S., Karlsdotter, K., & Levin, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00840-y · Cited by 10
Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes
Semova, I., Levenson, A. E., Krawczyk, J., Bullock, K. H., Williams, K., Wadwa, R. P., Khoury, P. R., Kimball, T. R., Urbina, E. M., de Ferranti, S. D., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13097 · Cited by 10
Dakhel, A., Zarrouk, M., Ekelund, J., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820960294 · Cited by 10
Self-citationTecce, N., Masulli, M., Palmisano, L., Gianfrancesco, S., Piccolo, R., Pacella, D., Bozzetto, L., Massimino, E., Pepa, G. D., Lupoli, R., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110001 · Cited by 11
Espinoza, M., Abbott, T., Passi‐Solar, Á., & Balmaceda, C. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00928-4 · Cited by 10
Shah, B. R., Austin, P. C., Ke, C., Lipscombe, L. L., Weisman, A., & Booth, G. L. (2023) · Diabetes Care · doi:10.2337/dc22-1936 · Cited by 10
Guo, X., Sang, C., Tang, R., Jiang, C., Li, S., Liu, N., Long, D., Du, X., Dong, J., & Ma, C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15043 · Cited by 10
Iwase, M., Ohkuma, T., Fujii, H., Oku, Y., Higashi, T., Oshiro, A., Ide, H., Nakamura, U., & Kitazono, T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110732 · Cited by 10
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 11
Corrales, P. J. P., Marcos, J. S., Gallardo, G. L., Moreno-Fernández, J., Antolín, S. H., López, I. Q., Zaballos, F. D. V., López, J. G., & Martínez, J. J. A. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.11.003 · Cited by 10
Blin, P., Joubert, M., Patrick Jourdain, M., Zaoui, P., Guiard, E., Sakr, D., Dureau‐Pournin, C., Bernard, M., Lassalle, R., Thomas‐Delecourt, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02101-1 · Cited by 10
Zhou, J. S., Wang, X., Tang, R., Kou, M., Ma, H., Li, X., Heianza, Y., Fonseca, V. A., & Qi, L. (2024) · BMC Medicine · doi:10.1186/s12916-024-03288-0 · Cited by 10
The 13C Glucose Breath Test Accurately Identifies Insulin Resistance in People With Type 1 Diabetes
Mertens, J., Roosens, L., Braspenning, R., Vandebeeck, J., Francque, S., & Block, C. E. M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae175 · Cited by 10
Chen, Y., Gialeli, C., Shen, J., Dunér, P., Walse, B., Duelli, A. S., Caing‐Carlsson, R., Blom, A. M., Zibert, J. R., Nilsson, A. H., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107259 · Cited by 11
Hu, C., Tkebuchava, T., & Wu, Q. (2024) · Cardiovascular Science · doi:10.35534/cvs.2024.10004 · Cited by 10
A review on cardiovascular effects of newer hypoglycaemic medications
Cutshall, B. T., Twilla, J. D., Olinger, A. S., & Oliphant, C. S. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1335428 · Cited by 10
Zimmermann‐Schlegel, V., Wild, B., Nawroth, P. P., Kopf, S., Herzog, W., & Hartmann, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-125445 · Cited by 10
Cause-Specific Mortality in Multiethnic South East Asians With Type 2 Diabetes Mellitus
Liu, J., Choo, R. W. M., Liu, S., Gurung, R. L., Wee, S. L., & Lim, S. C. (2019) · Asia Pacific Journal of Public Health · doi:10.1177/1010539519849317 · Cited by 10
Kattih, B., Elling, L. S., Weiß, C., Bea, M., Zwadlo, C., Bavendiek, U., Bauersachs, J. K., & Heineke, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-46640-8 · Cited by 10
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.008 · Cited by 10
Rocca, B., Rubboli, A., & Zaccardi, F. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880045 · Cited by 11
Sanadi, C. E. E., Ji, X., & Kattan, M. W. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4063 · Cited by 10
Zhao, X., Xu, L., Jiang, L., Tian, J., Zhang, Y., Wang, D., Sun, K., Xu, B., Zhao, W., Hui, R., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01193-3 · Cited by 10
Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer
Yuan, C., Zhang, X., Babić, A., Morales‐Oyarvide, V., Zhang, Y., Smith‐Warner, S. A., Wu, K., Wang, M., Wolpin, B. M., Meyerhardt, J. A., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1083 · Cited by 10
Wang, J., Liu, W.-J., & Lee, W. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211026391 · Cited by 10
Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent
Салухов, В. В., & Анатольевна, К. Е. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-10-21 · Cited by 10
Olomu, A. B., Kelly‐Blake, K., Hart-Davidson, W., Gardiner, J. C., Luo, Z., Heisler, M., & Holmes-Rovner, M. M. (2022) · Trials · doi:10.1186/s13063-022-06581-6 · Cited by 11
Diabetes and multivessel disease
Godoy, L. C., Rao, V. A., & Farkouh, M. E. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000550 · Cited by 10
Fritzen, K., Stautner, C., & Schnell, O. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107897 · Cited by 10
Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
Rankovic, M. R., Jeremic, N. S., Srejovic, I. M., Radonjić, K., Stojanović, A., Glišić, M., Bolevich, S. S., Bolevich, S., & Jakovljevic, V. L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10005-5 · Cited by 10
Amod, A., Buse, J. B., McGuire, D. K., Pieber, T. R., Pop‐Busui, R., Pratley, R. E., Zinman, B., Hansen, M. B., Jia, T., Mark, T., et al. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120970933 · Cited by 10
Self-citationZelenina, T. A., Салухов, В. В., Ab, Z., Zheleznyak, S. G., & Клиценко, О. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12372 · Cited by 10
de Miguel-Yanes, J. M., Jiménez‐García, R., Hernández‐Barrera, V., de Miguel‐Díez, J., Jiménez-Sierra, A., Zamorano‐León, J. J., Cuadrado‐Corrales, N., & López‐de‐Andrés, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02403-y · Cited by 9
Standl, E., & Schnell, O. (2025) · Cells · doi:10.3390/cells14080564 · Cited by 9
Strong development of research based on national quality registries in Sweden
Lysholm, J., & Lindahl, B. (2018) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2018.1520761 · Cited by 9
The perils of polyvascular disease in type 2 diabetes
Verma, S., Mazer, C. D., & Bhatt, D. L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30311-5 · Cited by 9
Tsuchida, K., Mitsuma, W., Sato, Y., Ozaki, K., Soda, S., Hatada, K., Tanaka, K., Hosaka, Y., Imai, S., Takahashi, K., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01394-7 · Cited by 9
Watanabe, Y., Saisho, Y., Inaishi, J., Kou, K., Yamauchi, A., Kanazawa, Y., Okubo, Y., Tokui, M., Imai, T., Murakami, R., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13146 · Cited by 9
Dakhel, A., Zarrouk, M., Ekelund, J., Acosta, S., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2020) · VASA · doi:10.1024/0301-1526/a000929 · Cited by 9
Self-citationZobel, E. H., von Scholten, B. J., Hansen, T. W., Persson, F., Rasmussen, S., Wolthers, B. O., & Rossing, P. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14578 · Cited by 9
Cederqvist, J., Rådholm, K., Muhammad, I. F., Engström, G., Engvall, J. E., & Östgren, C. J. (2023) · Diabetic Medicine · doi:10.1111/dme.15102 · Cited by 9
Serés‐Noriega, T., Ortega, E., Giménez, M., Perea, V., Boswell, L., Mariaca, K., Font, C., Mesa, A., Viñals, C., Blanco, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.025 · Cited by 9
Jing, R., Yao, H., Yan, Q., Xue, Y., Sun, W. R., Lu, P., Zhang, Z., Xie, R., Cui, B., & Feng, B. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.07.001 · Cited by 9
Pan, S., Yang, K., Shang, Y., Yu, R., Liu, L., Jin, J., & He, Q. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.015 · Cited by 9
Porto, A. D., Candido, R., Rocca, A., Manicardi, V., Nicolucci, A., Miranda, C., Cimino, E., Bartolo, P. D., Cianni, G. D., & Russo, G. T. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02327-0 · Cited by 9
Long-Term Risk of Type 2 Diabetes After Preterm Delivery or Hypertensive Disorders of Pregnancy
Crump, C., Sundquist, J., & Sundquist, K. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005604 · Cited by 9
Lee, H., Fernandes, M., Lee, J., Merino, J., & Kwak, S. H. (2025) · Diabetologia · doi:10.1007/s00125-025-06403-9 · Cited by 9
Wang, T., Wang, X., & Zhang, X. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2019.01.001 · Cited by 9
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.05.004 · Cited by 9
Südy, R., Peták, F., Schranc, Á., Agócs, S., Blaskovics, I., Lengyel, C., & Babik, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-56221-4 · Cited by 9
Kapelios, C. J., Bonou, M. S., Barmpagianni, A., Tentolouris, A., Tsilingiris, D., Eleftheriadou, I., Skouloudi, M., Kanellopoulos, P. N., Lambadiari, V., Masoura, C., et al. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107913 · Cited by 9
Aizawa, K., Casanova, F., Gates, P. E., Mawson, D. M., Gooding, K. M., Strain, W. D., Östling, G., Nilsson, J. Å., Khan, F., Colhoun, H. M., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17001 · Cited by 9
Lapébie, F.-X., Bongard, V., Lacroix, P., Aboyans, V., Constans, J., Boulon, C., Messas, E., Thomas‐Delecourt, F., Rosenbaum, D. H., Ferrières, J., et al. (2021) · Angiology · doi:10.1177/00033197211050144 · Cited by 9
The JUBILE cohort: Quality of life after more than 40 years with type 1 diabetes
Altman, J., Niarra, R., Balkau, B., & Vincent‐Cassy, C. (2020) · Diabetic Medicine · doi:10.1111/dme.14460 · Cited by 9
Zhang, X., Xu, D., Xu, P., Yang, S., Zhang, Q., Wu, Y., & Yuan, F. (2021) · Endocrine Connections · doi:10.1530/ec-21-0146 · Cited by 9
Soulimane, S., Balkau, B., Vogtschmidt, Y. D., Toeller, M., Fuller, J., & Soedamah‐Muthu, S. S. (2022) · Diabetologia · doi:10.1007/s00125-022-05698-2 · Cited by 9
Probing for Vulnerable Plaque in Patients With Diabetes Mellitus
Zaha, V. G., Joshi, P. H., & McGuire, D. K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312227 · Cited by 9
Self-citationRen, H., Zhao, L., Zou, Y., Wang, Y.-T., Zhang, J., Wu, Y., Zhang, R., Wang, T., Wang, J., Zhu, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14184906 · Cited by 9
Skriver-Møller, A.-C., Hasbak, P., Rasmussen, I. K. B., Blond, M. B., Wasehuus, V. S., Lassen, M. C. H., Lindhardt, M. K., Kofoed‐Enevoldsen, A., Kielgast, U. L., Zobel, E. H., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02717-5 · Cited by 8
Nishizawa, K., Tanaka, M., Sato, T., Gohda, T., Kamei, N., Murakoshi, M., Akiyama, Y., Kawaharata, W., Aida, H., Kouzu, H., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109146 · Cited by 8
Metabolic syndrome and the risk of incident heart failure: a prospective cohort study
Wei, H., Qiu, Z., Gao, Z., Wei, Y., Xiao, J., & Huang, W. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101279 · Cited by 8
Reassessing Revascularization Strategies in Coronary Artery Disease and Type 2 Diabetes Mellitus
Liang, B., He, X., & Gu, N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.738620 · Cited by 8
Babu, N. R., & Balasubramaniam, P. (2022) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2022.08.014 · Cited by 8
Luo, J., Tao, Y., Xu, Y., Yang, L., Zhang, H., Chen, Y., Liu, X., Zhang, Y., Lan, R., Chen, Y., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108518 · Cited by 8
Nadarajah, R., Ludman, P., Laroche, C., Appelman, Y., Brugaletta, S., Budaj, A., Bueno, H., Huber, K., Kunadian, V., Leonardi, S., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae002 · Cited by 8
Mohammedi, K., Fauchier, L., Quignot, N., Khachatryan, A., Banon, T., Kapnang, R., Kikuchi, K., Ren, H., Massien, C., Vigié, L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02257-4 · Cited by 8
Assessment of arterial stiffness in paediatric patients with type 1 diabetes mellitus
Georeli, E., Stamati, A., Dimitriadou, M., Chainoglou, A., Galli‐Τsinopoulou, A., Stabouli, S., & Christoforidis, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108782 · Cited by 8
Mechanisms and Therapeutic Strategies for Myocardial Ischemia-Reperfusion Injury in Diabetic States
Xue, J., Zhuang, J., Wang, X., Meng, T., Wu, J. Q., Zhang, X., & Zhang, G. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00272 · Cited by 10
Therapeutic Potential of Curcumin in Diabetic Cardiomyopathy: Modulation of Pyroptosis Pathways
Wang, F., Liu, L., Wang, J., Zhou, Y., Feng, X., & Liu, K. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07644-3 · Cited by 8
Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction
Nyström, T., Sartipy, U., Contardi, A., Lind, M., Bellocco, R., Eliasson, B., Svensson, A., & Holzmann, M. J. (2019) · Circulation · doi:10.1161/circulationaha.118.039223 · Cited by 8
Self-citationBersch-Ferreira, Â. C., Weber, B., da Silva, J. G. S. T., Pagano, R., Figueiró, M. F., da Silva, L. R., Mota, L. G. D. S., Suzumura, É. A., Torreglosa, C. R., Lara, E. D. S., et al. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200810131055 · Cited by 8
Dong, W., Wan, E. Y. F., Bedford, L. E., Wu, T., Wong, C. K. H., Tang, E. H. M., & Lam, C. L. K. (2020) · Public Health · doi:10.1016/j.puhe.2020.06.020 · Cited by 9
Taylor, G., Moser, O., Smith, K., Shaw, A., TANG, J. C. Y., Fraser, W. D., Eckstein, M. L., Aziz, F., Stevenson, E., Shaw, J., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001779 · Cited by 8
Butalia, S., Kaplan, G. G., Khokhar, B. A., Haubrich, S., & Rabi, D. M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s275080 · Cited by 8
Pujante, P., Torre, E. L. M., Morales-Sánchez, P., Escobedo, R. R., Barreiro, S. C., Rojo‐Martínez, G., & Delgado, E. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2020.12.040 · Cited by 8
Li, J., Chen, S., Ma, S., Yang, M., Qi, Z., Na, K., Qiu, M., Li, Y., & Han, Y. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/5352087 · Cited by 8
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Avgerinos, I., Liakos, A., Τσάπας, Α., & Bekiari, E. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s190356 · Cited by 8
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
